Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Zhang, Qiao ^a   Zhang, Yao ^a   Wang, Shi Z ^a   Wang, Ning ^a   Jiang, Wei G ^a   Ji, Yao H ^a   Zhang, Shu L ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

angiogenesis; apoptosis; cervical cancer; immunohistochemical study; Tissue factor pathway inhibitor 2

Indexed keywords

CD34 ANTIGEN; KI 67 ANTIGEN; PLACENTA PROTEIN 5; VASCULOTROPIN; GLYCOPROTEIN; TISSUE-FACTOR-PATHWAY INHIBITOR 2; VASCULOTROPIN A;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GROWTH; CANCER SURGERY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVESSEL DENSITY; NICK END LABELING; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; STAINING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; UTERINE CERVIX SQUAMOUS EPITHELIUM; WART VIRUS; CANCER STAGING; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; UTERINE CERVIX TUMOR; VASCULARIZATION;

ADULT; AGED; APOPTOSIS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855185784     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-1     Document Type: Article

References (32)

1. Cervical cancer. Waggoner SE, Lancet 2003 361 2217 2225 10.1016/S0140-6736(03)13778-6 12842378 (Pubitemid 36782559)
2. Chapter 5: updating the natural history of HPV and anogenital cancer. Moscicki AB, Schiffman M, Kjaer S, Villa LL, Vaccine 2006 24 suppl 3 42 51
3. Subcellularlocalization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulantonthe surface of syncytiotrophoblasts. Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Jin M, Miyagi E, Nakazawa T, Hirahara F, Miyazaki K, Miyagi Y, Placenta 2002 23 145 153 10.1053/plac.2001.0774 11945080 (Pubitemid 41110513)
4. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schönbeck U, J Clin Invest 2001 107 1117 1126 10.1172/JCI10403 11342575 (Pubitemid 32422908)
5. cDNA macroarray analysis of gene expression in synoviocytes stimulated with TNF alpha. Sugiyama T, Ishii S, Yamamoto J, Irie R, Saito K, Otuki T, Wakamatsu A, Suzuki Y, Hio Y, Ota T, Nishikawa T, Sugano S, Masuho Y, Isogai T, FEBS Lett 2002 517 121 128 10.1016/S0014-5793(02)02588-7 12062421 (Pubitemid 34327643)
6. HT-1080 fibrosarcoma cellmatrix degradationand invasion are inhibited by thematrix-associated serineprotease inhibitor TFPI-2/33 kDaMSPI. Rao CN, Cook B, LiuY Chilukuri K, Stack MS, Foster DC, Kisiel W, Woodley DT, Int JCancer 1998 76 749 756 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y (Pubitemid 28243950)
7. Structure function analysis of the reactive site in the first Kunitz type domain of human tissue factor pathway inhibitor-2. Chand HS, Schmidt AE, Bajaj SP, Kisiel W, J Biol Chem 2004 279 17500 17507 10.1074/jbc.M400802200 14970225 (Pubitemid 38560513)
8. Uterine cervical carcinoma: role of matrix metalloproteinases. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C, International Journal of Oncology 2009 34 897 904 19287946
9. Structure, function andbiology of tissue factor pathway inhibitor-2. Hitendra Chand S, Donald Foster C, Walter Kisiel, ThrombHaemost 2005 94 1122 1130
10. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. Shumin Wang, Xue Xiao, Xiaoying Zhou, Tingting Huang, Chunping Du, Nana Yu, Yingxi Mo, Longde Lin, Jinyan Zhang, Ning Ma, Mariko Murata, Guangwu Huang, Zhe Zhang, BMC Cancer 2010 10 617 10.1186/1471-2407-10-617 21062455
11. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO, Hepatology 2007 45 1129 1138 10.1002/hep.21578 17464989 (Pubitemid 46775774)
12. A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. Ran Y, Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L, Sun L, Liu J, Yang Z, Hum Gene Ther 2009 20 41 49 10.1089/hum.2008.129 20377370
13. Discovery of Novel Methylation Biomarers in Cervical Carcinoma by Global Demethylation and Microarray Analysis. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N, Cancer Epidemiol Biomarkers Prev 2006 15 114 123 10.1158/1055-9965.EPI-05-0323 16434596
14. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithetlium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Santin AD, Zhan F, Bignotti E, Siegel ER, Cané S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S, Virology 2005 331 269 291 10.1016/j.virol.2004. 09.045 15629771 (Pubitemid 40075455)
15. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Iino M, Foster DC, Kisiel W, Arterioscler Thromb Vasc Biol 1998 18 40 46 10.1161/01.ATV.18.1.40 9445254 (Pubitemid 28047597)
16. Transcriptional Silencing of the TFPI-2 Gene by Promoter Hypermethylation in Choriocarcinoma Cells. Hubé F, Reverdiau P, Iochmann S, Rollin J, Cherpi-Antar C, Gruel Y, Biol Chem 2003 384 1029 1034 10.1515/BC.2003.115 12956419 (Pubitemid 37062963)
17. Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Gessler F, Voss V, Seifert V, Gerlach R, Kögel D, Neurosci Lett 2011 497 49 54 10.1016/j.neulet.2011.04.027 21530612
18. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Konduri SD, Tasiou A, Chandrasekar N, Rao JS, Int J Oncol 2001 18 127 131 11115549
19. Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. Tang Z, Geng G, Huang Q, Xu G, Hu H, Chen J, Li J, J Surg Res 2011 167 62 69 10.1016/j.jss.2009.06.015 20018303
20. Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. Iochmann S, Bléchet C, Chabot V, Saulnier A, Amini A, Gaud G, Gruel Y, Reverdiau P, Clin Exp Metastasis 2009 26 457 467 10.1007/s10585-009-9245-z 19267203
21. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L, Kisiel W, Thromb Haemost 2003 90 140 146 12876637 (Pubitemid 36873870)
22. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Rollin J, Iochmann S, Blechet C, Hube F, Regina S, Guyetant S, Lemarie E, Reverdiau P, Gruel Y, British Journal of Cancer 2005 92 775 783 10.1038/sj.bjc.6602298 15685245 (Pubitemid 40460617)
23. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. Hongshen Guo, Yifeng Lin, Hongwei Zhang, Juan Liu, Nong Zhang, Yiming Li, Desheng Kong, Qiqun Tang, Duan Ma, BMC Molecular Biology 2007 8 110 10.1186/1471-2199-8-110 18053161 (Pubitemid 351659653)
24. A 2-year prospective study of human papilloma virus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group, J Infect Dis 2007 195 1582 1589 10.1086/516784 17471427 (Pubitemid 46799215)
25. HPV-mediated cervical carcinogenesis: concepts and clinical implications. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ, J Pathol 2006 208 152 164 10.1002/path.1866 16362994 (Pubitemid 43126109)
26. Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I, J Clin Pathol 1996 49 134 138 10.1136/jcp.49.2.134 8655679 (Pubitemid 26064919)
27. Restoration of TFPI-2 in a Human Glioblastoma Cell Line Triggers Caspase Mediated Pathway and Apoptosis. Joseph George, Christopher Gondi S, Dzung Dinh H, Meena Gujrati, Jasti Rao S, Clin Cancer Res 2007 13 3507 3517 10.1158/1078-0432.CCR-06-3023 17575213 (Pubitemid 46955110)
28. Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human brosarcoma cell line. Kempaiah P, Kisiel W, Apoptosis 2008 13 702 715 10.1007/s10495-008-0207-8 18401718
29. Molecular proling of angiogenesis markers. Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR, Am J Pathol 2002 161 35 41 10.1016/S0002-9440(10)64154-5 12107087
30. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, Brodie S, Kisiel W, Blood 2004 103 1069 1077 14525759 (Pubitemid 38129573)
31. Recombinant adenoassocia- ted virus (rAAV) exp ressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Yanamandra N, Kondraganti S, Gondi CS, Gujrati M, Olivero WC, Dinh DH, Rao JS, Int J Cancer 2005 115 998 1005 10.1002/ijc.20965 15723303 (Pubitemid 40791841)
32. Endothelial Cells Growth Factor and Suppresses Growth Factor-Induced Proliferation of Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial. Zhenhua Xu, Debasish Maiti, Walter Kisiel, Elia Duh J, Arterioscler Thromb Vasc Biol 2006 26 2819 2825 10.1161/01.ATV.0000248731.55781.87 17023682